3 completed, 1 recruiting, 1 withdrawn. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Thrombophilia: new trials by email Literature Review of Thrombophilia trials Research Report on Thrombophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers. BAY 3389934, Matching Placebo / Diluent - Sepsis Associated Disseminated Intravascular Coagulation (DIC) | Phase 1 | Completed | Bayer | 16 | 2025-09-22 | 2026-06-05 |
| A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy BAY3389934 - Sepsis, Coagulopathy | Phase 1 | Recruiting | Bayer | 36 | 2025-03-12 | 2026-10-16 |
| Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults cAd3-Marburg, cAd3-EBO-S - Ebola Virus Disease, Marburg Virus Disease | Phase 1 | Completed | Albert B. Sabin Vaccine Institute | 32 | 2021-01-06 | 2022-08-03 |
| A Study of KW-3357 in Congenital Antithrombin Deficiency KW-3357 - Congenital Antithrombin Deficiency | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 16 | 2009-04-01 | 2024-10-17 |
| Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura Rituximab - Thrombotic Thrombocytopenic Purpura | Phase 1 / Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2005-11-01 | 2012-11-15 |
Disseminated Intravascular Coagulation (3) · Hemostatic Disorders (2) · Sepsis (2) · Acquired Immunodeficiency Syndrome (1) · Acquired angioedema (1) · Angioedemas, Hereditary (1) · Antithrombin III Deficiency (1) · Communicable Diseases (1) · Creutzfeldt-Jakob Syndrome (1) · Hemorrhagic Fever, Ebola (1) · Hepatitis B (1) · Hepatitis C (1) · Marburg Virus Disease (1) · Purpura, Thrombotic Thrombocytopenic (1) · Thrombosis (1)
Blood Coagulation Disorders (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Cardiovascular Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Vascular Diseases (4) · Hemorrhagic Disorders (3) · Infections (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Inflammation (2) · Systemic Inflammatory Response Syndrome (2) · Angioedema (1)
Rituximab (1)
Bayer (2) · Albert B. Sabin Vaccine Institute (1) · Kyowa Kirin Co., Ltd. (1) · Weill Medical College of Cornell University (1)
United States (3) · Germany (2) · Belgium (1) · France (1) · Japan (1) · Netherlands (1) · Sweden (1) · United Kingdom (1)
Beverley Hunt, FRCP, FRCPath MD (1) · David Hoover, MD (1) · James B Bussel, M.D. (1) · Michael Stevenson, MD (1) · Roxana Rustomjee, MBChB (1) · Tuan Le, MD (1)
PMID 1538192, PMID 15577929, PMID 16375711, PMID 25426834, PMID 8237108